Relative carcinogenicity of tacrolimus < em > vs < /em > mycophenolate after solid organ transplantation and its implications for liver transplant care
CONCLUSION: The contrasting carcinogenic risk profiles of tacrolimus and MPA demonstrated in previous experimental studies, and its application in solid organ transplantation, is yet to be confirmed in clinical studies. Thus, the optimal choice of immunosuppression drug to use as maintenance monotherapy in LT recipients is not supported by a strong evidence base and remains unclear.PMID:38689747 | PMC:PMC11056899 | DOI:10.4254/wjh.v16.i4.650
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Dorothy Liu Mark M Youssef Josephine A Grace Marie Sinclair Source Type: research
More News: Cancer & Oncology | Databases & Libraries | Gastroenterology | Liver | Liver Transplant | Prograf | Study | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology